EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY-NC 4.0

Olaparib as treatment for platinum‐sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency: Phase 2 LIGHT study final overall survival analysis

Ying L Liu iD, Cara A Mathews, Fiona Simpkins iD, Karen A Cadoo, Diane Provencher, Colleen C McCormick, Adam C ElNaggar, Alon D Altman iD, Lucy Gilbert, Destin Black, Nashwa Kabil, Rosie N Taylor und 3 weitere

Cancer · 2025

DOI: 10.1002/cncr.35707 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Cancer, 2025. Verfasst von Ying L Liu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Memorial Sloan Kettering Cancer Center, New York, New York, USA. Hauptthemen laut MEDLINE: BRCA1 Protein, BRCA2 Protein, Neoplasm Recurrence, Local, Ovarian Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, AstraZeneca, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

LIGHT (oLaparib In HRD‐Grouped Tumor types; NCT02983799) prospectively evaluated olaparib treatment in patients with platinum‐sensitive relapsed ovarian cancer (PSROC) assigned to cohorts by known BRCA mutation (BRCAm) and homologous recombination deficiency (HRD) status: germline BRCAm (gBRCAm), somatic BRCAm (sBRCAm), HRD‐positive non‐BRCAm, and HRD‐negative. At the primary analysis, olaparib treatment demonstrated activity across all cohorts, with greatest efficacy in terms of objective response rate and progression‐free survival observed in the g/sBRCAm cohorts. The authors report final overall survival (OS).

Methods

In this phase 2, open‐label, noncomparative study, patients with PSROC and one or more prior line of platinum‐based chemotherapy were assigned to cohorts by BRCAm and HRD status. OS was a secondary end point. Tumors were analyzed using Myriad BRACAnalysis CDx and MyChoice CDx assays; HRD‐positive tumors were defined using a genomic instability score of ≥42.

Results

Of 272 enrolled patients, 271 received olaparib and 270 met the inclusion criteria for the efficacy analysis. At data cutoff, 18‐month OS rates in the gBRCAm, sBRCAm, HRD‐positive non‐BRCAm, and HRD‐negative cohorts were 86.4%, 88.0%, 78.6%, and 59.6%, respectively. No new safety signals were observed. In a post hoc analysis, patients on treatment for >18 months were most frequently present in g/sBRCAm cohorts (31.0%).

Conclusions

Olaparib treatment continued to demonstrate benefit across all cohorts. Consistent with the primary analysis, the highest OS rates were observed in the BRCAm cohorts, regardless of g/sBRCAm. In patients without a BRCAm, a higher OS rate was observed in the HRD‐positive non‐BRCAm than the HRD‐negative cohorts. These results highlight the importance of biomarker testing in this treatment setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BRCA1 ProteinBRCA2 ProteinNeoplasm Recurrence, LocalOvarian NeoplasmsPhthalazinesPiperazinesPoly(ADP-ribose) Polymerase InhibitorsAdultAgedFemaleHumansMiddle AgedGerm-Line MutationHomologous RecombinationMutationProgression-Free SurvivalProspective Studies

Stichwörter der Autor:innen

carcinomagenomic instabilitymutationolaparibovarian epithelialovarian neoplasmsplatinumpoly(ADP‐ribose) polymerase inhibitors

Substanzen

BRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanolaparibPhthalazinesPiperazinesPoly(ADP-ribose) Polymerase Inhibitors

Autor:innen und Institutionen

  • Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Weill Cornell Medical College, New York, New York, USA.
  • Program in Women's Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital, Legoretta Cancer Center, Brown University, Providence, Rhode Island, USA.
  • Department of Obstetrics and Gynecology, Jordan Center for Gynecologic Oncology at the Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • St. James's Hospital Dublin, Trinity St. James's Cancer Institute, Trinity College Dublin, Dublin, Ireland.
  • Division of Gynecologic-Oncology, Centre de recherche du Centre hospitalier de l'Université de Montréal, Montréal, Quebec, Canada.

ORCID-Profile: Ying L Liu, Fiona Simpkins, Alon D Altman

Förderung

  • NCI NIH HHS
  • AstraZeneca
  • Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Zitieren

APA

Liu, Y. L., Mathews, C. A., Simpkins, F., Cadoo, K. A., Provencher, D., McCormick, C. C., ElNaggar, A. C., Altman, A. D., Gilbert, L., Black, D., Kabil, N., Taylor, R. N., Barnicle, A., Munley, J. Y., & Aghajanian, C. (2025). Olaparib as treatment for platinum‐sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency: Phase 2 LIGHT study final overall survival analysis. Cancer. https://doi.org/10.1002/cncr.35707

Vancouver

Liu YL, Mathews CA, Simpkins F, Cadoo KA, Provencher D, McCormick CC, et al. Olaparib as treatment for platinum‐sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency: Phase 2 LIGHT study final overall survival analysis. Cancer. 2025. doi:10.1002/cncr.35707

BibTeX
@article{Liu2025,
  author = {Liu, Ying L and Mathews, Cara A and Simpkins, Fiona and Cadoo, Karen A and Provencher, Diane and McCormick, Colleen C and ElNaggar, Adam C and Altman, Alon D and Gilbert, Lucy and Black, Destin and Kabil, Nashwa and Taylor, Rosie N and Barnicle, Alan and Munley, Jiefen Y and Aghajanian, Carol},
  title = {Olaparib as treatment for platinum‐sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency: Phase 2 LIGHT study final overall survival analysis},
  journal = {Cancer},
  year = {2025},
  doi = {10.1002/cncr.35707}
}
Kostenlos starten →